Metabolic medicine
Does MSC therapy have a role in type 2 diabetes?
- Written by
- StemCell Longevita Editorial Team
- Medically reviewed by
- Prof. Dr. Erdal Karaöz TeamProfessor of Histology and Embryology · Medical Director, Center for Regenerative Medicine
- Last reviewed
- Next scheduled review
How we evaluate evidence · Conflict-of-interest disclosure · Editorial standards
There is real randomised human data here, and also a large gap between what it shows and what is advertised.
- Medically reviewed by:
- Prof. Dr. Erdal Karaöz, PhD
- Last reviewed:
- Next review:
The short answer
Randomised trials of MSC infusion in type 2 diabetes report modest reductions in HbA1c and insulin requirement in some participants over six to twelve months, without insulin independence. It is an adjunct to metabolic care, not a substitute for medication, diet or weight management, and it has no established role in type 1 diabetes outside trials.
Who this decision applies to
Usually appropriate to discuss
- Type 2 diabetes with documented HbA1c history over at least twelve months
- Metabolic therapy already optimised by an endocrinologist
- Residual beta-cell function and no acute complications
- Willingness to continue medication and monitoring throughout
Not appropriate right now
- Anyone hoping to stop insulin or oral agents after treatment
- Uncontrolled retinopathy, advanced nephropathy or active foot infection
- Type 1 diabetes outside a registered clinical trial
- Untreated obesity where lifestyle intervention has never been attempted
Evidence at a glance
The same five questions we ask of every indication, answered for this one.
| Question | Answer | What that means here |
|---|---|---|
| Human studies published? | Yes | Multiple published human trials of MSC infusion in type 2 diabetes. |
| Randomised controlled trials? | Yes | Randomised, placebo-controlled trials have been reported, mostly small. |
| Objective outcome measures? | Yes | HbA1c, C-peptide, insulin dose and HOMA-IR are the standard measures. |
| Long-term follow-up (≥12 months)? | Partly | Twelve-month data exist; longer follow-up is uncommon. |
| Approved as a routine therapy? | No | Not an approved diabetes treatment in any major jurisdiction. |
How these judgements are made: How we evaluate evidence · Editorial standards · Conflict-of-interest disclosure.
Options compared, including doing nothing
| Option | What it can realistically do | Main trade-off |
|---|---|---|
| Optimised medical therapy | Strong evidence for glycaemic and cardiovascular outcomes | Requires adherence and monitoring |
| Weight management and metabolic surgery | Largest effect on remission in eligible patients | Surgical risk; strict eligibility |
| MSC therapy as an adjunct | Modest HbA1c and insulin-dose reductions reported in trials | Not curative; effect size is small and variable |
| Continue current care | No cost, no travel, no new risk | Progressive disease if control is inadequate |
How the decision is made in practice
- We ask for twelve months of HbA1c values, current medication and C-peptide where available.
- We confirm endocrinology involvement, because dose adjustment after treatment must be supervised.
- We screen complications: retinopathy, nephropathy, neuropathy and foot status.
- We record baseline HbA1c, insulin dose and weight, and repeat at three, six and twelve months.
- Medication continues unchanged unless the endocrinologist adjusts it on the basis of readings.
When we decline, and why
- Requests framed as a way to come off insulin
- Advanced complications where risk outweighs any plausible benefit
- No endocrinology follow-up available at home
- Unwillingness to continue monitoring after treatment
Declining is a normal outcome of assessment, not a failure of it. See how candidacy and redirection work.
Questions worth asking any clinic
- What HbA1c change did the randomised trials actually report, and over what period?
- Who adjusts my medication after treatment, and how quickly?
- What cell type and dose is used, and what release testing has it passed?
- What is the review point at which we agree the treatment has not worked?
Frequently asked questions
No. Randomised trials report modest average reductions in HbA1c and insulin requirement rather than remission, and effects vary considerably between participants. Sustained weight loss and, in eligible patients, metabolic surgery remain the interventions most associated with remission.
We do not treat on that premise. Any dose change must be made by the doctor who manages your diabetes, based on your readings after treatment, and reductions when they occur are usually partial.
Those are separate indications with their own literature, and local cell-based approaches to foot ulcers have been studied specifically. They should be assessed on their own evidence rather than assumed to follow from systemic infusion.
Sources
- mesenchymal stem cells type 2 diabetes randomized controlled trial HbA1c — Randomised MSC trials reporting HbA1c outcomes.
- umbilical cord mesenchymal stromal cells type 2 diabetes insulin requirement — Cord-derived MSC studies and insulin requirement.
- mesenchymal stromal cells type 2 diabetes — Registered metabolic trials.
Citation practice and source hierarchy: How we evaluate evidence.
Related clinical questions
- Diabetes programme overview
- What the MSC evidence base actually shows
- Reading a cell release report
- Laboratory transparency report
Want this reviewed for your own case?
Send your diagnosis, imaging and medication list. If the answer is no, we will say so and explain why.
How to cite this page
This page's evidence table is published under CC BY 4.0. Reuse it with attribution and a link back.
| Style | Citation |
|---|---|
| APA | StemCell Longevita. (2026). Does MSC therapy have a role in type 2 diabetes?. StemCell Longevita. https://stemcelllongevita.com/clinical-decisions/type-2-diabetes-metabolic-candidacy |
| Vancouver | StemCell Longevita. Does MSC therapy have a role in type 2 diabetes? [Internet]. Istanbul: StemCell Longevita; 2026 [cited 2026-08-23]. Available from: https://stemcelllongevita.com/clinical-decisions/type-2-diabetes-metabolic-candidacy |
BibTeX:
@techreport{longevita_type_2_diabetes_metabolic_candidacy_2026,
title = {Does MSC therapy have a role in type 2 diabetes?},
author = {{StemCell Longevita}},
institution = {StemCell Longevita},
year = {2026},
url = {https://stemcelllongevita.com/clinical-decisions/type-2-diabetes-metabolic-candidacy},
urldate = {2026-08-23}
}Structured data: The evidence table on this page is also published as a machine-readable dataset descriptor. /cite